VEGFA and diabetes mellitus: To ascertain if any of the XMD8-92 treatment regimens are sufficient to halt diabetes-mediated VEGF, retinas were collected from non-diabetic (ND) and diabetic (DB) mice that received 100 μL of saline containing 5, 10, or 20 μM of XMD8-92 once every other week (light grey), once a week (dark grey), twice a week (black), or were untreated (white), 2 months after diabetes was confirmed (Figure 3).